Immunopathogenic Mechanisms and Novel Immune-Modulated Therapies in Rheumatoid Arthritis

International Journal of Molecular Sciences

Gu-Jiun Lin¹  Huey-Kang Sytwu²  Chia-Ning Chang³  Wan-Fu Hsu³  Chiung-Hsi Tien³  Hueng-Chuen Fan³  Shyi-Jou Chen³  Chih-Fen Hu³  Jing-Wun Chen⁴  Kai-Chen Wang⁵ 

[1] Department of Biology and Anatomy, National Defense Medical Center, No. 161, Section 6, MinChuan East Road, Neihu, Taipei City 114, Taiwan;Department of Microbiology and Immunology, National Defense Medical Center, No. 161, Section 6, MinChuan East Road, Neihu, Taipei City 114, Taiwan;Department of Pediatrics, Tri-Service General Hospital, National Defense Medical Center, No. 325, Section 2, Chenggong Rd., Neihu District, Taipei City 114, Taiwan;Graduate Institute of Life Sciences, National Defense Medical Center, No. 161, Section 6, MinChuan East Road, Neihu, Taipei City 114, Taiwan;School of Medicine, National Yang-Ming University, No. 155, Section 2, Linong Street, Taipei City 112, Taiwan;

关键词: anticitrullinated peptide antibodies;    antirheumatic drug;    autoimmune;    disease-modifying;    immunology;    pathology;    rheumatoid factor;   

DOI  :  10.3390/ijms20061332

来源: DOAJ

【 摘 要 】

Rheumatoid arthritis (RA) is a chronic, inflammatory autoimmune disease of unknown etiology. It is characterized by the presence of rheumatoid factor and anticitrullinated peptide antibodies. The orchestra of the inflammatory process among various immune cells, cytokines, chemokines, proteases, matrix metalloproteinases (MMPs), and reactive oxidative stress play critical immunopathologic roles in the inflammatory cascade of the joint environment, leading to clinical impairment and RA. With the growing understanding of the immunopathogenic mechanisms, increasingly novel marked and potential biologic agents have merged for the treatment of RA in recent years. In this review, we focus on the current understanding of pathogenic mechanisms, highlight novel biologic disease-modifying antirheumatic drugs (DMRADs), targeted synthetic DMRADs, and immune-modulating agents, and identify the applicable immune-mediated therapeutic strategies of the near future. In conclusion, new therapeutic approaches are emerging through a better understanding of the immunopathophysiology of RA, which is improving disease outcomes better than ever.

【 授权许可】

Unknown